Biolojic Design

What Biolojic Design does

Biolojic Design is an Israel-based biotechnology company that computationally designs antibodies and antibody-like therapeutics using machine learning models trained on proprietary datasets of billions of antibody measurements. The company's technology stack comprises two integrated platforms: an epitope-specific antibody design capability and a multibody platform that produces multi-specific, symmetrical IgG-format antibodies, complemented by a Small Molecule Exchanger platform. Biolojic's pipeline and partner assets include AU-007 (Imneskibart) — the first computationally designed antibody to enter clinical trials, an anti-IL-2 candidate out-licensed to Aulos Bioscience for solid tumors; BD9 (now TEV '325), a dual-specific IL-13/TSLP multibody exclusively licensed to Teva; BD200, a Trop-2/Nectin-4 multibody-drug conjugate for oncology; and undisclosed programs under collaboration with Eli Lilly, Nektar Therapeutics, and Merck KGaA.

The company operates a B2B pharmaceutical partnership model, generating revenue through upfront payments, R&D funding, milestone payments tied to development and regulatory progress, and royalties on partnered programs. Named counterparties include Merck KGaA (multi-target deal worth up to €346 million), Teva, Nektar Therapeutics, Eli Lilly, and Aulos Bioscience. Biolojic Design was founded by Prof. Yanay Ofran and is led by Ofran as CEO with Avraham Molcho as Chairman, supported by a senior team including COO Micah Pearlman (ex-Teva), CSO Ronald Herbst, and a CMO appointed in January 2026 from Novartis. The company maintains 11–50 employees and operates from Israel with a US presence at Children's National Hospital in Washington, DC.

Peer-reviewed work in Nature, Cell Reports, and Nucleic Acids Research, together with multiple patents on computational antibody design, substantiates the in-house AI capability. The primary business risk is concentration on a small number of pharma counterparties and the lumpiness of milestone-driven revenue; the principal upside is the reusable nature of the multibody and Small Molecule Exchanger chassis, which allows each new design to be deployed across multiple partners and indications.

Name

Biolojic Design

Legal name

Biolojic Design Ltd.

Website

https://biolojic.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Biolojic Design is an Israel-based biotech that computationally designs antibodies and multibody therapeutics using machine learning trained on billions of antibody measurements, licensing candidates to pharma partners including Merck KGaA, Teva, Nektar, and Eli Lilly.

Ownership category

akta.pro rank

Product category

Therapeutic Antibodies

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)

akta.pro secondary industries

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds) (HLAAAAAJ), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

Keywords

• Computational antibody design
• AI antibody engineering
• Multispecific antibody therapeutics
• Immuno-oncology biologics
• Biotech drug discovery

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Partnership and Licensing Revenue: Biolojic enters into partnerships with pharmaceutical companies where they receive upfront payments, research funding, and are eligible for milestone payments tied to preclinical, clinical, regulatory, and commercial achievements. They also receive tiered royalties on net product sales.
2. Research Collaborations: Multi-target drug discovery collaborations with upfront payments and research funding, such as the Merck KGaA partnership valued at up to €346 million including milestones and royalties.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

Biolojic Design is an AI-native biotech company that uses machine learning to computationally design programmable human antibodies. Its platform engineers two classes of therapeutic molecules - epitope-specific antibodies and multibodies (multi-specific symmetrical IgG antibodies) - for autoimmune diseases and immuno-oncology. The company discovers candidates in-house and licenses them to large pharmaceutical partners for downstream development and commercialization.

Product overview

Biolojic Design is a computational biology company that has developed an AI-powered antibody design platform. The company's portfolio includes three clinical-stage programs: AU-007 (Imneskibart), a computationally designed IL-2 antibody in Phase 1/2 for solid tumors; TEV '325 (formerly BD9), a dual-specific multibody for inflammatory diseases licensed to Teva; and BD200, a Trop-2/Nectin-4 targeting multibody-drug conjugate expected to enter clinical trials in 2026. The platform supports epitope-specific antibody design and multibody technology for multi-specific therapeutics.

Differentiator

Problem solved

Functional benefit

Brands

• Aulos Bioscience: A spinout company launched in collaboration with ATP (a life sciences venture capital firm) developing interleukin-2 (IL-2) binding monoclonal antibodies as therapeutics against solid tumors. Currently advancing AU-007 through Phase 1/2 clinical trials.

Products and services

• AU-007 (Imneskibart)
• TEV '325 (formerly BD9)
• BD200
• Small Molecule Exchanger A multibody platform concept that binds circulating chemotherapy in the periphery and releases it in the tumor micro-environment to increase the therapeutic index of chemotherapeutics and reduce off-tumor toxicity.

Quantifiable outcome

• AU-007 showed clinical activity in heavily pre-treated patients whose tumors progressed through checkpoint inhibitors, including disease control and objective response results
• +2 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

Partnerships

Six partnerships are on record, tiered core and minor.

• Merck & Co. (referenced as Merck in partnership context)coreStrategic or Co-development Partner · 1 January 2026Cooperation agreement with pharmaceutical giant Merck (alongside Teva and Nektar Therapeutics) mentioned in context of companies having raised over $200 million combined for research.
• Merck KGaA, Darmstadt, GermanycoreStrategic or Co-development Partner · 1 June 2024Multi-target drug discovery collaboration announced June 2024. Biolojic's AI-driven discovery platform will be used to design therapeutic antibodies for cancer and immunological disorders. Biolojic receives low double-digit million euro upfront payment and research funding, with eligibility for discovery, development, regulatory and commercial milestone payments up to €346 million plus tiered royalties on net product sales.
• Teva Pharmaceutical IndustriescoreOEM/ Whitelabel/ Licensing Partner · 1 December 2023Exclusive license agreement for BD9 (now TEV '325), a dual-specific antibody blocking both TSLP and IL-13 for atopic dermatitis and asthma treatment. Teva holds exclusive worldwide rights to develop, manufacture and globally commercialize. BD9 is the first AI-designed multibody in development and supports Teva's Pivot to Growth strategy.
• Eli Lilly and CompanyminorStrategic or Co-development Partner · 1 March 2021Research collaboration announced March 2021 to discover and develop antibody therapies for diabetes using Biolojic's AI platform.
• Nektar TherapeuticscoreStrategic or Co-development Partner · 1 February 2021Research partnership to develop an antibody modulating TNFR2 pathway to agonize T regulatory cells for autoimmune diseases. In April 2024, Nektar exercised its license option following successful preclinical studies and has been advancing the program through IND-enabling studies since late December 2023. Biolojic entitled to development milestones and sales royalties.
• Aulos BiosciencecoreStrategic or Co-development Partner · 1 January 2021Spinout company launched with ATP (life sciences venture capital) to develop AU-007, an IL-2 binding monoclonal antibody for solid tumors. AU-007 advanced to Phase 1/2 human trial in Australia. Early data showed clinical activity including disease control and objective responses in heavily pre-treated patients.

Scale indicators4 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• Absci: Absci is a public AI generative biology company designing de novo antibodies using its proprietary AI platform and E. coli expression system. Direct competitor in AI-designed antibody therapeutics with similar pharma partnership model and pipeline breadth.
• Adimab: Adimab provides antibody discovery and engineering services to pharma partners using a proprietary yeast-based platform with computational design elements. Closely comparable in partnership-driven business model serving the same pharma customer base.
• BigHat Biosciences: BigHat Biosciences combines ML with high-throughput wet-lab experiments to design antibody therapeutics, with similar AI-driven antibody design focus. Closely comparable as a smaller, antibody-focused AI design platform with pharma partnerships.
• AbCellera Biologics: AbCellera operates an AI-powered antibody discovery platform partnering with pharma companies to develop therapeutic antibodies. Direct comparable in business model (partnership/licensing with pharma) and platform technology focus, with more mature clinical pipeline.
• Generate Biomedicines: Generate Biomedicines is a generative biology platform designing novel protein therapeutics using AI/ML, including antibodies and multi-specifics. Most direct competitor to Biolojic in AI-designed biologics with significantly larger funding (>$700M raised) and broader therapeutic scope.

Broad incumbents

• Isomorphic Labs: Alphabet/DeepMind-backed Isomorphic Labs applies AlphaFold-derived AI to drug design across small molecules and biologics. A well-capitalized adjacent player using AI for therapeutic protein and antibody discovery with pharma partnerships (Eli Lilly, Novartis).
• Insilico Medicine: Insilico Medicine operates an AI-driven drug discovery platform spanning multiple modalities and therapeutic areas, including biologics. Broader scope than Biolojic but overlaps in AI-enabled drug discovery and pharma partnership model.

Emerging players

• Antiverse: Antiverse designs functional antibodies using a combination of AI/ML and in vitro display technologies, focusing on difficult targets. Direct comparable as a smaller AI antibody design platform with similar pharma-partnered business model.
• Twist Bioscience: Twist Bioscience provides DNA synthesis and antibody discovery services, including its Twist Biopharma division using AI/ML tools for antibody optimization. Comparable as an antibody-focused platform serving pharma partners, though more emphasis on synthesis and library infrastructure.
• Cradle Bio: Cradle applies generative AI to protein design across multiple modalities including antibodies. Comparable in AI-driven protein/antibody engineering approach but broader therapeutic scope and earlier stage.

Market position

Strengths5 records

Weaknesses3 records

Competitive moat5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biolojic Design